Characterization of antibody responses against the 2F5 epitope ELDKWA sing HIV-1 Env-mediated membrane fusion and neutralization assays

被引：0
作者：
Cao Y. [1 ,2 ]
Chen Y. [1 ,2 ]
机构：
[1] Laboratory of Immunology, Department of Biological Sciences and Biotechnology, Tsinghua University
[2] Beijing Key Laboratory for Protein Therapeutics
来源：
Tsinghua Science and Technology | 2010年 / 15卷 / 04期
关键词：
ELDKWA epitope; HIV-1; monoclonal antibodies; neutralization;
D O I：
10.1016/S1007-0214(10)70086-9
中图分类号：
学科分类号：
摘要：
The epitope ELDKWA, which is located in the membrane-proximal external region (MPER) of HIV-1 gp41, is an important neutralizing epitope. The human monoclonal antibody (mAb) 2F5 against this epitope shows broad neutralizing activity toward many HIV strains. However, several reports have shown that the epitope-specific mAbs induced by peptides containing MPER did not exhibit the same neutralizing activities as human mAb 2F5. In this study, four ELDKWA epitope specific mAbs (9E7, 7E10, 6B5, and 2B4) induced by immunization with the ELDKWA epitope in varied molecular contexts, all showed inhibitory activities with different potencies in HIV-1 Env-mediated membrane fusion assays and pseudovirus neutralization assays. This result indicates that though these antibodies recognize the epitope ELDKWA, their characterizations differ from that of neutralizing antibodies, implying that the neutralizing mAbs can be induced but also need to be screened, and the protective ability of a related vaccine antigen depends on the concentration of the neutralizing mAbs in the induced polyclonal antibodies. © 2010 Tsinghua University Press.
引用
收藏
页码：447 / 451
页数：4
相关论文
共 22 条
  • [11] Zhang G., Lu H., Lu Y., Et al., Neutralization of HIV-1 primary isolate by ELDKWA-specific murine monoclonal antibodies, Immunobiology, 210, pp. 639-645, (2005)
  • [12] Weiss C.D., White J.M., Characterization of stable of Chinese hamster overy cells expressing wild-type, secreted, and glycosylphosphatidylinositol-anchored human immunodeficiency virus type 1 envelope glycoprotein, J. Virol., 67, pp. 7060-7066, (1993)
  • [13] Hong P., Chan N., Kandil A., Et al., A strategy for rational design of fully synthetic glycopeptide conjugate vaccines, Infection and Immunity, 65, pp. 4918-4925, (1997)
  • [14] Liu W., Zou P., Chen Y.H., High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity, Vaccine, 23, pp. 366-371, (2004)
  • [15] Kohler G., Milstein C., Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 256, pp. 495-497, (1975)
  • [16] Moore J.P., Alexandra T., HIV type 1 coreceptors, neutralization serotypes, and vaccine development, AIDS Research and Human Retroviruses, 13, pp. 733-736, (1997)
  • [17] Parren P.W., Mondor I., Sattentau Q.J., Et al., Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity, J. Virol., 72, pp. 3512-3519, (1998)
  • [18] Liang X., Munshi S., Shiver J.W., Et al., Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein, Vaccine, 17, pp. 2862-2872, (1999)
  • [19] Eckhart L., Raffelsberger F., Et al., Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus, J. Gen. Virol., 77, pp. 2001-2008, (1996)
  • [20] Burton D.R., Williamson R.A., Parren P.W., Antibody and virus: Binding and neutralization, J. Virol., 270, pp. 1-3, (2000)
123